Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls.

Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF.

Am J Hematol. 2015 Jun 25. doi: 10.1002/ajh.24098. [Epub ahead of print]

PMID:
26113113
2.

Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.

Chang JM, McCullough AE, Dueck AC, Kosiorek HE, Ocal IT, Lidner TK, Gray RJ, Wasif N, Northfelt DW, Anderson KS, Pockaj BA.

Ann Surg Oncol. 2015 May 22. [Epub ahead of print]

PMID:
26001860
3.

Multidisciplinary Shared Decision Making in the Management of Ductal Carcinoma In Situ of the Breast.

Parikh P, Pockaj B, Wasif N, Halyard M, Wong W, Kosiorek HE, Dueck AC, Gray R.

Ann Surg Oncol. 2015 May 19. [Epub ahead of print]

PMID:
25986869
4.

Predictive Testing for Alzheimer's Disease: Suicidal Ideation in Healthy Participants.

Caselli RJ, Marchant GE, Hunt KS, Henslin BR, Kosiorek HE, Langbaum J, Robert JS, Dueck AC.

Alzheimer Dis Assoc Disord. 2015 May 12. [Epub ahead of print] No abstract available.

PMID:
25984909
5.

Rates of residual disease with close but negative margins in breast cancer surgery.

Garvey EM, Senior DA, Pockaj BA, Wasif N, Dueck AC, McCullough AE, Ocal IT, Gray RJ.

Breast. 2015 Aug;24(4):413-7. doi: 10.1016/j.breast.2015.03.005. Epub 2015 Apr 4.

PMID:
25845608
6.

Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).

Dueck AC, Singh J, Atherton P, Liu H, Novotny P, Hines S, Loprinzi CL, Perez EA, Tan A, Burger K, Zhao X, Diekmann B, Sloan JA; Alliance for Clinical Trials in Oncology.

Osteoporos Int. 2015 Jul;26(7):1971-7. doi: 10.1007/s00198-015-3091-4. Epub 2015 Mar 7.

PMID:
25749740
7.

Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.

Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Nagi Reddy SK, Gano K, Dueck AC, Stewart AK.

Br J Haematol. 2015 Apr;169(2):219-27. doi: 10.1111/bjh.13296. Epub 2015 Feb 13.

PMID:
25683772
8.

Sex-based memory advantages and cognitive aging: a challenge to the cognitive reserve construct?

Caselli RJ, Dueck AC, Locke DE, Baxter LC, Woodruff BK, Geda YE.

J Int Neuropsychol Soc. 2015 Feb;21(2):95-104. doi: 10.1017/S1355617715000016. Epub 2015 Feb 9.

PMID:
25665170
9.

Association of hospital participation in a surgical outcomes monitoring program with inpatient complications and mortality.

Etzioni DA, Wasif N, Dueck AC, Cima RR, Hohmann SF, Naessens JM, Mathur AK, Habermann EB.

JAMA. 2015 Feb 3;313(5):505-11. doi: 10.1001/jama.2015.90.

PMID:
25647206
10.

Quality of life and disease understanding: impact of attending a patient-centered cancer symposium.

Padrnos L, Dueck AC, Scherber R, Glassley P, Stigge R, Northfelt D, Mikhael J, Aguirre A, Bennett RM, Mesa RA.

Cancer Med. 2015 Jun;4(6):800-7. doi: 10.1002/cam4.422. Epub 2015 Jan 30.

11.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM.

J Clin Oncol. 2015 Mar 1;33(7):701-8. doi: 10.1200/JCO.2014.57.6298. Epub 2015 Jan 20.

PMID:
25605861
12.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D.

J Natl Cancer Inst. 2014 Sep 29;106(9). pii: dju244. doi: 10.1093/jnci/dju244. Print 2014 Sep.

PMID:
25265940
13.

Public perceptions of presymptomatic testing for Alzheimer disease.

Caselli RJ, Langbaum J, Marchant GE, Lindor RA, Hunt KS, Henslin BR, Dueck AC, Robert JS.

Mayo Clin Proc. 2014 Oct;89(10):1389-96. doi: 10.1016/j.mayocp.2014.05.016. Epub 2014 Aug 26.

PMID:
25171823
14.

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA.

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.

PMID:
25117817
15.

Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, Minasian LM, Denicoff AM, O'Mara AM, Fisch MJ, Chauhan C, Aaronson NK, Coens C, Bruner DW.

J Natl Cancer Inst. 2014 Jul 8;106(7). pii: dju129. doi: 10.1093/jnci/dju129. Print 2014 Jul. Review.

16.

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.

Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA.

Blood. 2014 Jun 12;123(24):3803-10. doi: 10.1182/blood-2013-09-527903. Epub 2014 Feb 19.

17.

Fracture risk perception study: patient self-perceptions of bone health often disagree with calculated fracture risk.

Grover ML, Edwards FD, Chang YH, Cook CB, Behrens MC, Dueck AC.

Womens Health Issues. 2014 Jan-Feb;24(1):e69-75. doi: 10.1016/j.whi.2013.11.007.

PMID:
24439949
18.

Depressive symptoms in healthy apolipoprotein E ε4 carriers and noncarriers: a longitudinal study.

Locke DE, Dueck AC, Stonnington CM, Knopman DS, Geda YE, Caselli RJ.

J Clin Psychiatry. 2013 Dec;74(12):1256-61. doi: 10.4088/JCP.13m08564.

19.

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G.

Breast Cancer Res Treat. 2014 Feb;143(3):485-92. doi: 10.1007/s10549-013-2827-0. Epub 2014 Jan 7.

20.

Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.

McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, Castle EP, Gray RJ, Wasif N, Goetz MP, Hawse JR, Henry TJ, Barrett MT, Cunliffe HE, Pockaj BA.

Ann Surg Oncol. 2014 Feb;21(2):361-7. doi: 10.1245/s10434-013-3260-7. Epub 2013 Sep 18.

PMID:
24046116
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk